Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NVAX - Novavax, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.00
DETAILS
HIGH:
$25.00
LOW:
$11.00
MEDIAN:
$18.00
CONSENSUS:
$18.00
UPSIDE:
61.65%
Stock News
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened
Novavax, Inc. (NASDAQ: NVAX - Get Free Report) shares traded down 9.1% during trading on Friday. The stock traded as low as $11.57 and last traded at $11.6480. Approximately 2,002,169 shares traded hands during trading, a decline of 61% from the average session volume of 5,124,194 shares. The stock had previously closed at $12.82. Wall Street
Novavax shareholder Shah Capital to step back from activist role
Novavax shareholder Shah Capital to step back from activist role
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?
Shares of Novavax, Inc. (NASDAQ: NVAX - Get Free Report) were up 10.5% during mid-day trading on Monday. The company traded as high as $11.25 and last traded at $11.5620. 3,160,292 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 4,772,155 shares. The stock had previously closed at $10.46.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $11.27, marking a -10.31% move from the previous day.
Novavax Stock Falls Back: What's Going On?
Novavax Inc. (NASDAQ:NVAX) shares are pulling back Tuesday after a more than 20% surge Monday. Vaccine stocks rallied after a suspected pneumonic plague case in Russia.
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novavax Shorts on Edge as Russia Plague Fears Spread
A suspected plague death at a Siberian research institute has investors reaching for the pandemic playbook again. One of biotech's most heavily shorted stocks is posting the biggest gain.
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $10.79, denoting a +1.53% move from the preceding trading day.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.
Price Targets
Novavax initiated with an Overweight at Cantor Fitzgerald
$18.00
(was $8.55)
Cantor Fitzgerald
Novavax price target raised to $11 from $10 at H.C. Wainwright
$11.00
(was $8.46)
Sean Lee
·
H.C. Wainwright
Novavax (NVAX) PT Lowered to $22 at B.Riley
$22.00
(was $7.58)
Mayank Mamtani
·
B.Riley Financial
Novavax (NVAX) PT Lowered to $25 at Jefferies
$25.00
(was $10.15)
Roger Song
·
Jefferies
Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial'
$14.00
(was $10.45)
Alec Stranahan
·
Bank of America Securities
Novavax price target lowered to $31 from $38 at Jefferies
$31.00
(was $14.36)
Roger Song
·
Jefferies
H.C. Wainwright reiterates Buy rating on Novavax after 'landmark' Sanofi deal
$19.00
(was $9.94)
Vernon Bernardino
·
H.C. Wainwright
Novavax (NVAX) Stock: $174 Price Target From Cantor Fitzgerald
$174.00
(was $80.11)
Charles Duncan
·
Cantor Fitzgerald